Table 1.
Expected and observed levels of rds and rom1 monomers in mouse retinas
| Genotype | rds expected (% w/t) | rds observed (% w/t ± SEM) | rom1 expected (% w/t) | rom1 observed (% w/t ± SEM) |
|---|---|---|---|---|
| Wild-type | 100 | (100) | 100 | (100) |
| rom1+/− | 100 | 106 ± 4 | 50 | 58 ± 2 |
| L185Prds+/− | 100 | 62 ± 2 | 100 | 103 ± 2 |
| Digenic | 100 | 51 ± 2 | 50 | 42 ± 2 |
| rds+/− | 50 | 26 ± 2 | 100 | 67 ± 2 |
| P216L rds+/− | 100 | 8 ± 1 | 100 | 25 ± 3 |
| rom1−/− | 100 | 100 ± 4 | 0 | 0 |
| S231A rds+/− | 50 | 45 ± 4 | 100 | 99 ± 10 |
Expected levels of rds and rom1 monomers relative to wild-type (w/t) were based on measurements of the respective endogenous and transgenic mRNAs by nuclease protection analysis without considering the effects of reduced protein stability or outer-segment dysplasia. Observed levels of rds and rom1 were obtained by quantitative immunoblotting, as represented in Fig. 5a. Values are expressed as an average percent of the wild-type signal on each blot ± SEM. For S231A rds+/− mice, contributions of the nonglycosylated protein (lower rds band in Fig. 5a) were not included.